Overview

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

Status:
Recruiting
Trial end date:
2022-07-28
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
Phase:
Phase 3
Details
Lead Sponsor:
Shenyang Tonglian Group CO., Ltd